Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 in Relapsed Sensitive or Refractory SCLC
NCT01266018Phase 2Terminated
- Sponsor
- Ludwig Cancer Research
- Start
- Jan 2011
- Primary completion
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of Pegargiminase in small cell lung cancer (SCLC), sponsored by Ludwig Cancer Research. Started Jan 2011; status: terminated.
02
Drugs
Pegargiminase
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01266018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01266018.